Nicolas Abreu

Dr. Nicolas Abreu

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2020 in Pediatric Pulmonology
Verified
Journal Article
Closed access
PDF file
NANicolas Abreu
Nicolas Abreu
MWMegan A. Waldrop
Megan A. Waldrop

11 February 2022 in Clinical Case Reports
Verified
Journal Article
Open access
PDF file
NANicolas Abreu
Nicolas Abreu
ASAmy E. Siemon
Amy E. Siemon
ABAdriane L. Baylis
Adriane L. Baylis
RKRichard E. Kirschner
Richard E. Kirschner
RPRuthann B. Pfau
Ruthann B. Pfau
KTKristen V. Truxal
Kristen V. Truxal
KMT2E‐related neurodevelopmental disorder is a recently described intellectual disability syndrome often with speech difficulties. Here, we describe an individual with a heterozygous frameshift variant in KMT2E (NM_182931.2:c.2334_2337delTTAC, p.[Tyr779AlafsTer41]), intellectual disability, cerebellar hypoplasia, and velopharyngeal dysfunction. This case suggests potential mechanisms of speech disturbance in the disorder, requiring further investigation.

10 August 2022 in Advances in Neurodevelopmental Disorders
Verified
Journal Article
Open access
PDF file
NANicolas Abreu
Nicolas Abreu
MCMadeline Chiujdea
Madeline Chiujdea
SSSarah J. Spence
Sarah J. Spence
Objectives: While national medical guidelines recommend genetic testing for all individuals with non-syndromic autism spectrum disorder (ASD), there is underutilization of genetic testing. This study aims to define the perspectives and approaches to initial genetic testing of ASD diagnosticians in order to improve utilization. Methods: A prospective cross-sectional study was conducted using an anonymous online survey distributed to 59 staff neurologists, developmental-behavioral pediatricians, psychologists, post-graduate physician fellows, and nurse practitioners from a single academic medical center. Questions explored knowledge, attitudes, and practices of initial genetic testing for ASD among diagnosticians. Results: Among the 30 respondents (51% response rate), a lack of comprehensive pre-test genetic counseling was identified and forgetfulness was the most prevalent reason for not recommending genetic testing (n = 7/23, 30%). Insurance prior authorization (PA) for genetic testing was a major barrier for clinicians. More than half of respondents (n = 13/25, 52%) reported being uncomfortable with the PA process. Conclusions: Variability in knowledge and practices among ASD diagnosticians regarding genetic testing was identified. Therefore, potential interventions like clinician and administrative staff education, as well as genetic counselor integration into ASD clinics, may be useful to improve genetic testing utilization.

12 December 2024 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
CSCosima M. Schmid
Cosima M. Schmid
AGAnne Gregor
Anne Gregor
ARAnna Ruiz
Anna Ruiz
CBCarmen Manso Bazús
Carmen Manso Bazús
IHIsabella Herman
Isabella Herman
CZChristiane Zweier
Christiane Zweier
While mostly de novo truncating variants in SCAF4 were recently identified in 18 individuals with variable neurodevelopmental phenotypes, knowledge on the molecular and clinical spectrum is still limited. We assembled data on 50 novel individuals with SCAF4 variants ascertained via GeneMatcher and personal communication. With detailed evaluation of clinical data, in silico predictions and structural modeling, we further characterized the molecular and clinical spectrum of the autosomal dominant SCAF4-associated neurodevelopmental disorder. The molecular spectrum comprises 25 truncating, eight splice-site and five missense variants. While all other truncating variants were classified as pathogenic/likely pathogenic, significance of one C-terminal truncating variant, one splice-site variant and the missense variants remained unclear. Three missense variants in the CTD-interacting domain of SCAF4 were predicted to destabilize the domain. Twenty-three variants occurred de novo, and variants were inherited in 13 cases. Frequent clinical findings were mild developmental delay with speech impairment, seizures, and skeletal abnormalities such as clubfoot, scoliosis or hip dysplasia. Cognitive abilities ranged from normal IQ to severe intellectual disability (ID), with borderline to mild ID in the majority of individuals. Our study confirms the role of SCAF4 variants in neurodevelopmental disorders and further delineates the associated clinical phenotype.

1 November 2020 in Expert Opinion on Orphan Drugs
Verified
Journal Article
Closed access
SAShawn C. Aylward
Shawn C. Aylward
JPJonathan Pindrik
Jonathan Pindrik
NANicolas Abreu
Nicolas Abreu
WCW. Bruce Cherny
W. Bruce Cherny
MOMatthew O’neal
Matthew O’neal
EREmily de Los Reyes
Emily de Los Reyes
Introduction: Neuronal ceroid lipofuscinosis type 2 (CLN2) is a rare, lysosomal storage disease that causes progressive neurodegeneration in children. Cerliponase alfa enzyme replacement therapy is the first approved treatment for CLN2. Areas covered: This article reviews the clinical presentation of CLN2, significant preclinical and clinical studies related to the approvals of cerliponase alfa enzyme replacement therapy (ERT) and other future disease modifying therapies like gene transfer. Authors also describe standard and novel surgical approaches and practical infusion considerations. Authors performed a comprehensive literature review using PubMed and ISI web of science. Inclusive dates of search were from September to October 2020. Expert opinion: Prior to the approval of cerliponase alfa ERT, treatment was limited to symptomatic and palliative approaches. Cerliponase alfa intracerebroventricular therapy offers a safe and effective treatment option with long-term delay of disease progression. Current research indicates treated children have better outcomes in comparison to their natural history counterparts allowing preserved ambulation and language. Future research should be directed toward the discovery of therapies that may allow the delivery or promote production of functional CLN2 protein such as gene therapy.

3 December 2013 in Case Reports in Radiology
Verified
Journal Article
Open access
PDF file
SMSophia K. McKinley
Sophia K. McKinley
NANicolas Abreu
Nicolas Abreu
EPEva Patalas
Eva Patalas
ACArthur Chang
Arthur Chang
While inguinal hernia is common in the primary care office, the differential diagnosis is extensive and includes infectious, inflammatory and neoplastic processes. Varicocele is another frequent, generally benign condition which occasionally reflects serious disease entities. Left-sided or bilateral varicoceles account for the overwhelming majority of varicoceles because the left gonadal vein drains into the left renal vein in contrast to the right gonadal vein, which drains directly into the inferior vena cava, thus making left-sided or bilateral venous congestion more likely. Presence of an uncommon unilateral right-sided varicocele thus warrants further radiological workup, in particular CT abdomen and pelvis, to evaluate for retroperitoneal pathology. We describe a case in which appropriate use of a variety of imaging modalities including testicular ultrasound and CT led to an important diagnosis of a large, well-differentiated liposarcoma in the right retroperitoneum of a patient with a right-sided groin mass.